This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Determine the overall rates of and risk factors for AIDS-defining complications and serious bacterial infections in subjects in the parent study, ACTG 362. Secondary 1. Determine the overall rates and risk factors (e.g. triglycerides, cholesterol, waist-to-hip ratio) for the development of cardiovascular disease in the study cohort. Cardiovascular events of interest include: myocardial infarction, coronary artery revascularization procedures, angina, sudden cardiac death, and stroke. 2. Compare the time to development of AIDS-defining complications and serious infections or cardiovascular disease in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 3. Evaluate the association between CD4 counts and HIV RNA levels at baseline and during follow-up and risk of opportunistic infections and other HIV-related complications. 4. Compare mortality in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 5. Define the risk of cognitive deterioration in a cohort of patients who have been severely immunosuppressed and recovered CD4 counts while taking Highly Active Antiretroviral Therapy (HAART). 6. Identify immunologic (CD4 counts) and virologic (plasma HIV RNA levels) markers and specific drugs (especially PIs) associated with cognitive decline. 7. Evaluate factors associated with long-term adherence to antiretroviral medications and the effect of adherence on viral suppression over time and on the development of opportunistic and serious bacterial infections and cardiovascular disease.
Showing the most recent 10 out of 589 publications
